Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 12 04:00PM ET
1.12
Dollar change
+0.04
Percentage change
3.70
%
Index- P/E- EPS (ttm)-0.27 Insider Own3.98% Shs Outstand74.42M Perf Week-5.08%
Market Cap119.33M Forward P/E- EPS next Y-0.31 Insider Trans0.00% Shs Float73.92M Perf Month-2.61%
Income-20.31M PEG- EPS next Q-0.08 Inst Own1.79% Short Float3.59% Perf Quarter14.29%
Sales0.00M P/S- EPS this Y-0.70% Inst Trans-16.88% Short Ratio6.12 Perf Half Y-5.08%
Book/sh0.09 P/B12.88 EPS next Y-2.35% ROA-78.05% Short Interest2.65M Perf Year-22.76%
Cash/sh0.14 P/C8.22 EPS next 5Y- ROE-144.22% 52W Range0.84 - 1.75 Perf YTD-17.04%
Dividend Est.- P/FCF- EPS past 5Y18.01% ROI-278.00% 52W High-36.00% Beta1.68
Dividend TTM- Quick Ratio2.99 Sales past 5Y0.00% Gross Margin- 52W Low33.32% ATR (14)0.08
Dividend Ex-Date- Current Ratio2.99 EPS Y/Y TTM13.19% Oper. Margin0.00% RSI (14)47.87 Volatility6.36% 6.46%
Employees27 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin- Recom1.12 Target Price4.95
Option/ShortNo / Yes LT Debt/Eq0.09 EPS Q/Q14.34% Payout- Rel Volume1.28 Prev Close1.08
Sales Surprise- EPS Surprise-16.98% Sales Q/Q- EarningsNov 12 BMO Avg Volume433.21K Price1.12
SMA20-5.92% SMA503.29% SMA2005.48% Trades Volume551,501 Change3.70%
Date Action Analyst Rating Change Price Target Change
Oct-06-22Initiated Maxim Group Buy $3
Feb-17-21Initiated H.C. Wainwright Buy $15
Today 02:08AM
Nov-12-24 07:00AM
Nov-11-24 07:00AM
Oct-15-24 07:32AM
Oct-07-24 11:21AM
09:00AM Loading…
Oct-04-24 09:00AM
07:00AM
Sep-24-24 09:15AM
Sep-20-24 11:08AM
09:00AM
Sep-19-24 12:08PM
07:00AM
Sep-06-24 08:00AM
Aug-12-24 04:37PM
07:45AM
07:00AM Loading…
Aug-02-24 07:00AM
Aug-01-24 04:01PM
Jul-24-24 07:00AM
Jun-27-24 03:28PM
07:00AM
Jun-24-24 07:00AM
Jun-21-24 06:53AM
Jun-20-24 05:26PM
10:00AM
08:45AM
07:26AM
Jun-19-24 01:09PM
Jun-12-24 10:22AM
Jun-04-24 09:55AM
Jun-03-24 09:17AM
01:24PM Loading…
May-28-24 01:24PM
May-24-24 12:16PM
08:45AM
07:00AM
May-23-24 11:51AM
May-17-24 12:50PM
May-16-24 07:00AM
May-15-24 11:14AM
08:03AM
07:00AM
May-10-24 04:35PM
May-09-24 08:59PM
04:21PM
04:01PM
12:15PM
10:26AM
08:08AM
07:00AM
May-08-24 07:00AM
May-03-24 12:15PM
Apr-30-24 10:30AM
07:00AM
Apr-25-24 07:00AM
Apr-11-24 09:15AM
07:00AM
Apr-02-24 07:00AM
Mar-14-24 08:45AM
Mar-10-24 08:36AM
Mar-07-24 09:55PM
04:01PM
Mar-06-24 08:00AM
Mar-05-24 08:30AM
07:00AM
Mar-04-24 07:00AM
Feb-28-24 07:00AM
Feb-15-24 08:00AM
Feb-14-24 08:30AM
07:00AM
Feb-07-24 08:55AM
Jan-09-24 10:25AM
07:00AM
Jan-04-24 07:00AM
Dec-07-23 07:00AM
Nov-29-23 10:45AM
Nov-09-23 08:45AM
07:00AM
06:30AM
Nov-05-23 02:29PM
Nov-03-23 12:03PM
07:00AM
Oct-23-23 09:50AM
08:45AM
07:05AM
07:00AM
Oct-20-23 10:31AM
07:00AM
Oct-16-23 07:00AM
Oct-13-23 09:00AM
Oct-11-23 09:00AM
Sep-26-23 08:00AM
Sep-19-23 07:00AM
Sep-07-23 09:22AM
Sep-06-23 07:00AM
Aug-21-23 07:00AM
Aug-17-23 09:35AM
Aug-14-23 07:00AM
Aug-08-23 08:50AM
Aug-04-23 07:05AM
07:00AM
Jul-31-23 06:55AM
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.